Fatty liver disease (MASLD/MASH) trials in Japan

In Japan 10 Also abroad 367

10 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Where
Kawasaki-shi, Ōgaki
Age
18 years to 75 years
People
1,740 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07701993
Phase 3Taking people
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Where
Kawasaki-shi, Ōgaki
Age
18 years to 75 years
People
380 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07704892
Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Bunkyō City, Chiba, Chiba, Ichikawa, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu, Hanishina-gun, Hiroshima, Hokkaido, Sapporo, Hyogo, Nishinomiya, Ibaraki, Inashiki-gun, Isehara-Shi, Ishikawa, Kanazawa, Izumo, Kagoshima, Kanagawa, Kawasaki, Kawasaki-shi, Kita-gun, Kobe, Kumamoto, Kure, Kyoto, Miyazaki, Musashino, Nagano, Matsumoto, Nagasaki, Omura, Nara, Kashihara, Narita, Niigata, Ōita, Okayama, Osaka, Saga, Sakai, Sapporo, Sendai, Shimonoseki, Shiwa-gun, Shizuoka, Hamamatsu, Shizuoka, Izunokuni, Suita-shi, Suita-Shi, Takasaki-shi, Tokyo, Tokyo, Bunkyo-ku, Tokyo, Minato-ku, Toyoake-shi, Tsu, Wakayama, Yokohama
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Bunkyō City, Chiba, Ehime, Toon, Fukui-shi, Fukuoka, Fukuoka, Fukuoka, Kurume, Gifu, Gifu, Gifu, Ogaki, Hanishina-gun, Hiroshima, Hokkaido, Sapporo, Ibaraki, Inashiki-gun, Isehara-Shi, Ishikawa, Kanazawa, Izumo, Kagoshima, Kanagawa, Kawasaki, Kita-gun, Kobe, Kumamoto, Kure, Kyoto, Miyazaki, Musashino, Nagano, Matsumoto, Nagasaki, Omura, Nara, Kashihara, Narita, Niigata, Nishinomiya, Ōita, Okayama, Osaka, Saga, Sakai, Sapporo, Sendai, Shiwa-gun, Shizuoka, Hamamatsu, Shizuoka, Izunokuni, Suita-shi, Suita-Shi, Takasaki-shi, Tokyo, Tokyo, Bunkyo-ku, Tokyo, Minato-ku, Toyoake-shi, Tsu, Wakayama, Yokohama
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Ehime, Fukuoka, Gifu, Hizume, Kawasaki, Kumamoto, Maebashi, Nagano, Okayama, Osaka, Saga, Sapporo, Yokohama
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Where
Bunkyō-Ku, Fukui-shi, Kyoto, Maebashi, Minato-Ku, Musashino, Ōgaki, Shinjuku, Suita-shi, Wakayama, Yokohama
Age
18 years to 80 years
People
2,150 worldwide
Run by
Akero Therapeutics, Inc
See details and how to joinNCT06528314
Phase 2Taking people
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Where
Sapporo
Age
18 years to 75 years
People
120 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05519475
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Amagasaki, Asahikawa, Bunkyō, Bunkyō City, Chikushino-shi, Fukuoka, Gifu, Ginowan, Hamamatsu, Hiroshima, Ichikawa, Izumo, Izunokuni, Kagoshima, Kashihara, Kawasaki, Kita-ku, Kofu, Kumamoto, Kurume, Kyoto, Maebashi, Minatoku, Musashino-shi, Nagasaki, Nagoya, Narita, Nishinomiya, Ōgaki, Ōita, Okayama, Ōmura, Osaka, Saga, Sakai, Sapporo, Shimotsuke, Shinjuku-ku, Shinjyuku-ku, Shiwa-gun Yahaba-cho, Suita, tabashi City, Takamatsu, Takasaki, Tokyo, Tomitake, Tōon, Toshimaku, Tsu, Ureshino, Yamagata, Yokohama
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Gunma, Kagoshima
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
Phase 3Taking people
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Where
Gifu, Kanagawa, Kyoto, Musashino, Yokohama
Age
18 years to 75 years
People
1,200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221227